Takotsubo Cardiomyopathy
Details
Takotsubo cardiomyopathy (TTS; stress cardiomyopathy; apical ballooning syndrome) is an acute, transient LV dysfunction syndrome — classified by the International Takotsubo Registry authors as an acute heart failure syndrome with morbidity and mortality comparable to ACS. Named after the Japanese octopus-pot trap (takotsubo), the characteristic apical LV shape was first described in Japan in 1990. It predominantly affects postmenopausal women and is often — but not always — preceded by a stressor. The catecholamine-excess hypothesis has long been proposed but remains unproven, and empirical beta-blocker therapy has not demonstrated survival benefit.
Key Facts
Epidemiology and Demographics
- n=1,750 International Takotsubo Registry (26 centres; 9 countries; 1998–2014; Mayo Clinic diagnostic criteria). (sources/takotsubo-nejm-2015, rating: high)
- 89.8% women; mean age 66.8 years. (sources/takotsubo-nejm-2015, rating: high)
- Physical triggers (36.0%) more common than emotional triggers (27.7%); no evident trigger in 28.5% — contradicts the common assumption that emotional stress is the primary precipitant. (sources/takotsubo-nejm-2015, rating: high)
- Neuropsychiatric comorbidity: 55.8% of TTS vs 25.7% of ACS (P<0.001) — the strongest differentiating feature from ACS in this registry. (sources/takotsubo-nejm-2015, rating: high)
- Coexisting CAD in 15.3% — does not exclude the diagnosis (Mayo Clinic criteria allow this exception). (sources/takotsubo-nejm-2015, rating: high)
Morphology
- Apical (classic): 81.7%
- Midventricular: 14.6%
- Basal: 2.2%
- Focal: 1.5% (sources/takotsubo-nejm-2015, rating: high)
ECG and Biomarkers (vs ACS)
- Troponin elevated in 87% — but only ×1.8 ULN (vs ×6 in ACS); troponin magnitude useful for differentiation
- CK elevation absent — clinically useful negative marker
- BNP/NT-proBNP ×5.9 ULN — disproportionate elevation vs troponin
- QTc prolongation substantial in acute phase
- ST depression only 8.3% vs 31.1% in ACS (sources/takotsubo-nejm-2015, rating: high)
Haemodynamics
- Mean LVEF 40.7±11.2% on admission vs 51.5±12.3% in ACS (P<0.001)
- LVEDP >11 mmHg in 93% — universal acute diastolic dysfunction (sources/takotsubo-nejm-2015, rating: high)
In-Hospital Complications
- Serious in-hospital complications: 21.8% — equal to ACS (P=0.93); TTS is not a benign condition
- VT: 3.0%; LV thrombus: 1.3%; free wall rupture: 0.2%
Independent predictors of complications (multivariable): (sources/takotsubo-nejm-2015, rating: high)
- ↑ Risk: physical trigger, acute neurological or psychiatric disease, troponin >10× ULN, LVEF <45% on admission
- ↓ Risk: older age, emotional trigger
Short-Term Outcomes
- 30-day MACCE: 7.1% overall; men 13.7% vs women 6.3% (sources/takotsubo-nejm-2015, rating: high)
Long-Term Outcomes
| Endpoint | Rate |
|---|---|
| All-cause death | 5.6%/year |
| MACCE | 9.9%/year |
| Recurrence | 1.8%/year |
| Stroke/TIA | 1.7%/year |
- Sex disparity: Men 12.9%/yr vs women 5.0%/yr all-cause death (P<0.001) — men represent only ~10% of cases but have markedly worse prognosis. (sources/takotsubo-nejm-2015, rating: high)
Treatment Evidence
- ACEi/ARB: improved 1-year survival (P=0.001 after propensity matching) — the only medication class with a survival signal. (sources/takotsubo-nejm-2015, rating: high)
- Beta-blockers: NO survival benefit (P=0.72 after propensity matching):
- 32.5% of patients were already on beta-blockers when TTS occurred
- 29 of 57 recurrences occurred while on beta-blockers
- Empirical beta-blocker use is widespread based on the catecholamine hypothesis, but outcome data do not support it. (sources/takotsubo-nejm-2015, rating: high)
- No randomised treatment trials: All treatment evidence is observational/propensity-adjusted; no prospective RCT data exist for TTS pharmacotherapy.
Diagnostic Criteria (Mayo Clinic)
Used as registry inclusion criteria (with exceptions):
- Transient LV wall-motion abnormality beyond a single epicardial coronary artery territory
- Absence of obstructive CAD or angiographic acute plaque rupture
- New ECG abnormalities or troponin elevation
- Absence of pheochromocytoma and myocarditis
Exceptions allowed: coexisting CAD; wall-motion abnormality congruent with a single coronary territory if all other criteria met; death in acute phase before wall-motion recovery.
Contradictions / Open Questions
- Beta-blocker use without evidence: Beta-blockers are widely prescribed empirically based on the catecholamine hypothesis, yet this registry found no survival benefit after propensity adjustment. 32.5% of patients were on BBs at TTS onset; 29/57 recurrences occurred on BBs. Until an RCT is conducted, empirical beta-blocker use lacks outcome support. (sources/takotsubo-nejm-2015, rating: high)
- Physical triggers outnumber emotional — but disease is called "stress cardiomyopathy": Physical triggers (36%) are more prevalent than emotional triggers (27.7%); nearly 29% have no trigger. The popular narrative of emotional stress as the dominant precipitant is a misconception driven by early case reports. (sources/takotsubo-nejm-2015, rating: high)
- Pathophysiology unresolved: Catecholamine excess, multivessel spasm, microvascular dysfunction, and direct neurogenic myocardial injury (via the concepts/Brain-Heart-Axis) have all been proposed. No single mechanism has been confirmed, and no proven pathophysiology-directed therapy exists. (sources/takotsubo-nejm-2015, rating: high)
- Recurrence despite beta-blockers: 29 of 57 recurrences occurred while patients were on beta-blockers — raising questions about whether beta-blockers have any recurrence-preventing effect. (sources/takotsubo-nejm-2015, rating: high)
Connections
- Related to entities/Heart-Failure — TTS classified as an acute HF syndrome; in-hospital complications = ACS
- Related to concepts/Brain-Heart-Axis — neuropsychiatric comorbidity 55.8%; autonomic/catecholamine mechanism hypothesis
- Related to concepts/Acute-Heart-Failure — presentation and haemodynamics
- Related to entities/ACS — ACS is the principal differential diagnosis; ECG/biomarker differences; matched comparison cohort